Dasatinib: Difference between revisions
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Dasatinib, also known as Sprycel ([[____]])"/> ===Better Known as: Sprycel=== * Marketed By: ... |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* Major Indication: Chronic Myelogenous [[Cancer|Leukemia]] (CML) | * Major Indication: Chronic Myelogenous [[Cancer|Leukemia]] (CML) | ||
* Drug Class: Receptor Tyrosine Kinase (Especially, PDGFR, KIT & BCR-Abl) Inhibitor | * Drug Class: Receptor Tyrosine Kinase (Especially, PDGFR, KIT & BCR-Abl) Inhibitor | ||
* Date of FDA Approval (Expiration): | * Date of FDA Approval (Expiration): 2006 (2020) | ||
* | * 2009 Global Sales: $421 Million | ||
* Importance: It is a second generation receptor Tyrosine kinase inhibitor. It binds to Abl with less stringent conformational requirements so it exhibits increased potency compared to [[Imatinib]] although with less selectivity. Unlike most RTK inhibitors, Dasatinib binds the active conformation of BCR-Abl. Is used to treat patients with certain Imatinib resistant forms of [[Cancer|CML]]. Controversial due to its nearly $50,000 per year cost.<ref>doi:10.1056/NEJMoa055229</ref> | |||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||